Bionano Genomics to Present at the 2022 H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Bionano Genomics, Inc. (BNGO) will participate virtually in the 2022 H.C. Wainwright Global Investment Conference. The presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time. Erik Holmlin, PhD, President and CEO, will provide a company overview. Bionano specializes in optical genome mapping solutions and diagnostic software, aiming to transform genome analysis in research and medicine. Interested individuals can register for the conference and access the presentation online.

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present a company overview available for on-demand listening starting Tuesday, May 24, 2022, at 7:00 a.m. Eastern Time. Interested parties can register for the conference and view the presentation here: www.hcwevents.com/globalconference.

About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit bionanogenomics.com, lineagen.com or biodiscovery.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com 

FAQ

When will Bionano Genomics participate in the H.C. Wainwright Global Investment Conference?

Bionano Genomics will participate in the conference on May 24, 2022, at 7:00 a.m. Eastern Time.

Who will present for Bionano Genomics at the conference?

Erik Holmlin, PhD, the President and CEO of Bionano Genomics, will present at the conference.

How can I watch Bionano Genomics' presentation at the conference?

The presentation will be available for on-demand listening starting May 24, 2022, and can be accessed by registering at the event's website.

What is the focus of Bionano Genomics?

Bionano Genomics focuses on optical genome mapping solutions and diagnostic software for biological and medical research.

Where can I find more information about Bionano Genomics?

More information about Bionano Genomics can be found on their official website, bionanogenomics.com.